Efficacy and safety of infliximab therapy and predictors of response in korean patients with crohn’s disease: A nationwide, multicenter study

Keyphrases

• Crohn's Disease 100%
• Korean Patients 100%
• Response Predictors 100%
• Infliximab 100%
• Infliximab Therapy 100%
• Adverse Events 60%
• Perianal Crohn's Disease 60%
• Clinical Response 40%
• Sustained Response 40%
• Maintenance Therapy 40%
• Induction Therapy 40%
• Clinical Remission 40%
• Sustained Remission 40%
• Clinical Outcomes 20%
• Male Gender 20%
• Referral Center 20%
• Serious Adverse Events 20%
• Remission Rate 20%
• Active Tuberculosis 20%
• Colonic Diseases 20%
• Active Crohn's Disease 20%
• Response Event 20%

Medicine and Dentistry

• Patient with Crohn's Disease 100%
• Infliximab 100%
• Crohn's Disease 85%
• Adverse Event 57%
• Maintenance Therapy 28%
• Clinician 14%
• Lung Tuberculosis 14%
• Infusion 14%
• Spontaneous Remission 14%
• Patient Referral 14%
• Colon Disease 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Crohn's Disease 100%
• Infliximab 100%
• Remission 62%
• Adverse Event 50%
• Lung Tuberculosis 12%
• Colon Disease 12%